Effectiveness of flouroquinolone therapy for gram-negative infections within the intensive care unit setting.
Hassoun
Ali
A
Eiland
Edward
E
D000150:Acinetobacter / Q000187:drug effects; D000407:Alabama; D002939:Ciprofloxacin / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D016972:Enterobacter cloacae / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D024841:Fluoroquinolones / Q000494:pharmacology / Q000627:therapeutic use*; D000077734:Gatifloxacin; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006764:Hospitals, Community; D006801:Humans; D007362:Intensive Care Units; D041121:Klebsiella oxytoca / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000627:therapeutic use; D011513:Proteus mirabilis / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012189:Retrospective Studies
D024841:Fluoroquinolones; D002939:Ciprofloxacin; D015242:Ofloxacin; D000077734:Gatifloxacin